Article
Long-Acting Rilpivirine (RPV) Preexposure Prophylaxis Does Not Inhibit Vaginal Transmission of RPV-Resistant HIV-1 or Select for High-Frequency Drug Resistance in Humanized Mice.
Journal of virology - 31 Mar 2020
Melody Kevin, Roy Chandra N, Kline Christopher, Cottrell Mackenzie L, Evans Dwayne, Shutt Kathleen, Pennings Pleuni S, Keele Brandon F, Bility Moses, Kashuba Angela D M, Ambrose Zandrea
Abstract excerpt
As a long-acting formulation of the nonnucleoside reverse transcriptase inhibitor rilpivirine (RPV LA) has been proposed for use as preexposure prophylaxis (PrEP) and the prevalence of transmitted RPV-resistant viruses can be relatively high, we evaluated the efficacy of RPV LA to inhibit vaginal transmission of RPV-resistant HIV-1 in humanized mice. Vaginal challenges of wild-type (WT), Y181C, and Y181V HIV-1...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.